Welcome to the US! Polish Selvita has announced its new US HQ in Cambridge (MA), which they hope will better integrate their drug-discovery work into the US market.
Selvita, from Krakow (Poland) is the largest Polish biotech with 265+ employees, 86 of which hold PhDs. Having been built on offering pre-clinical services to over 50 US/EU clients, Selvita has grown to develop its own pipeline in diseases from Parkinson’s to Alzheimers, with an overwhelming emphasis in Oncology.
After an IPO of €6.5M last December and being listed on the Warsaw Stock Exchange, their latest strategic move to plant a base in Cambridge (MA) is in the hope of reducing the distance between them and their US clients, for which the Boston biotech valley is the valuable hotspot.
Marketing Manager of Selvita, Natalia Baranowska, affirmed that if Selvita was really going to take off, a Boston base is the only way forward.
“If you’re in biotech, you’ve got to be in Cambridge.”
Despite this grand-plan however,